This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfeffer, M. A. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Pfeffer, M. A. Articles by Braunwald, E.

Influence of baseline lipids on effectiveness of pravastatin in the CARE trial

Marc A. Pfeffer, MD, PhD, FACC^a, Frank M. Sacks, MD^a, Lemuel A. Moyé, MD, PhD^*, Cara East, MD, Steven Goldman, MD, FACC, David T. Nash, MD, FACC, Jacques R. Rouleau, MD, FACC^||, Jean Lucien Rouleau, MD, FACC^¶, Bruce A. Sussex, MD, FACC^#, Pierre Theroux, MD, FACC^¶, Ron J. Vanden Belt, MD, FACC^** and Eugene Braunwald, MD, FACC^a

^a Department of Medicine, Brigham and Women’s Hospital and Harvard School of Public Health, Boston, Massachusetts, USA
^* Department of Medicine University of Texas School of Public Health, Houston, Texas, USA
Department of Medicine Baylor University, Dallas, Texas, USA
Department of Medicine Veterans Affairs Medical Center, Tucson, Arizona, USA
Department of Medicine State University of New York Health Science Center, Syracuse, New York, USA
^|| Department of Medicine Laval Hospital, Ste-Foy, Quebec, Canada
^¶ Department of Medicine Montreal Heart Institute, Quebec, Canada
^# Department of Medicine Health Sciences Center, St. John’s, Newfoundland, Canada
^** Department of Medicine Michigan Heart and Vascular Institute (author deceased), USA

View larger version (19K): [in a new window]   Figure 1 Relation of quartiles of baseline total cholesterol and subsequent coronary events for placebo (line with circles) and pravastatin (line with squares) groups. The upper two lines are the cumulative event rates for the secondary end point of either fatal coronary heart disease (CHD), nonfatal MI, coronary artery bypass graft surgery or angioplasty. The lower two lines are the primary cumulative event rates for either coronary heart disease death or nonfatal MI.

View larger version (18K): [in a new window]   Figure 2 Relation of quartiles of LDL cholesterol and subsequent coronary events for placebo (line with circles) and pravastatin (line with squares) groups. The upper two lines are the cumulative event rates for the secondary end point of either fatal coronary heart disease (CHD), nonfatal MI, coronary artery bypass graft surgery or angioplasty. The lower two lines are the primary cumulative event rates for either coronary heart disease death or nonfatal MI.

View larger version (18K): [in a new window]   Figure 3 Relation of quartiles of HDL cholesterol and subsequent coronary events for placebo (line with circles) and pravastatin (line with squares) groups. The upper two lines are the cumulative event rates for the secondary end point of either fatal coronary heart disease (CHD), nonfatal MI, coronary artery bypass graft surgery or angioplasty. The lower two lines are the primary cumulative event rates for either coronary heart disease death or nonfatal MI.

View larger version (20K): [in a new window]   Figure 4 Relation of quartiles of triglycerides and subsequent coronary events for placebo (line with circles) and pravastatin (line with squares) groups. The upper two lines are the cumulative event rates for the secondary end point of either fatal coronary heart disease (CHD), nonfatal MI, coronary artery bypass graft surgery or angioplasty. The lower two lines are the primary cumulative event rates for either coronary heart disease death or nonfatal MI.

View larger version (16K): [in a new window]   Figure 5 Kaplan-Meier estimates of the incidence of coronary heart disease death or nonfatal MI in subgroups of CARE patients, constructed by baseline lipids for eligibility in 4S. RR = relative risk reduction.